Coixol
Based on 1 publication(s) in Google Scholar
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level.
For research use only. We do not sell to patients.
- Purity : 98.56%
- CAS No.: 532-91-2
- Formula: C8H7NO3
- Molecular Weight:165.15
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Coixol
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | IC50 |
>100 μM
Compound: 1; 2a
|
Cytotoxicity against mouse RAW264.7 cells incubated for 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells incubated for 24 hrs by MTT assay
|
[PMID: 37561816] |
| RAW264.7 | IC50 |
31.2 μM
Compound: 1; 2a
|
Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 37561816] |
| RAW264.7 | IC50 |
48.9 μM
Compound: 1; 2a
|
Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 37561816] |
| RAW264.7 | IC50 |
66.4 μM
Compound: 1; 2a
|
Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 37561816] |
In Vitro
Coixol (5, 10, 20 µM, 2+24 h) decreases the iNOS protein expression in LPS-induced RAW264.7 Cells[2].
Coixol (0.03, 0.1, 0.3, 1, 3, 10, 30, 100 μM; 1+24 h) inhibits the production of TNF-α, IL-6, and IL-1β with IC50s of 31.2, 48.9, 66.4 µM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 cells
-
Concentration:5, 10, 20 µM
-
Incubation Time:2 h and then stimulated with or without LPS (0.5 μg/mL) for 24 h
-
Result:Decreased the iNOS protein expression in a dose dependent manner.
In Vivo
Coixol (25, 50 mg/kg, p.o.; daily for 15 day) decreases the blood glucose levels in a dose- and time-dependent manner in type 2 diabetic rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:9–12 weeks, Sprague Dawley (SD) male rats[3]
-
Dosage:25, 50 mg/kg
-
Administration:P.o.
-
Result:Decreased the blood glucose levels significantly, improved glucose tolerance.
Chemical Information
-
CAS No. 532-91-2
-
Appearance Solid
-
Molecular Weight 165.15
-
Formula C8H7NO3
-
Color Light brown to brown
-
SMILES
O=C1OC2=CC(OC)=CC=C2N1
-
Synonyms
6-Methoxy-2-benzoxazolinone; 6-MBOA
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (605.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (15.14 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (15.14 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yusheng Hu, et al. Coixol Suppresses NF-κB, MAPK Pathways and NLRP3 Inflammasome Activation in Lipopolysaccharide-Induced RAW 264.7 Cells. Molecules [Content Brief]
[2]. Cui E, et al. Discovery of Coixol Derivatives as Potent Anti-inflammatory Agents. J Nat Prod. 2023 Aug 25;86(8):1950-1959. [Content Brief]
[3]. Hameed A, et al. Coixol amplifies glucose-stimulated insulin secretion via cAMP mediated signaling pathway. Eur J Pharmacol. 2019 Sep 5;858:172514. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.0551 mL | 30.2755 mL | 60.5510 mL | 151.3775 mL |
| 5 mM | 1.2110 mL | 6.0551 mL | 12.1102 mL | 30.2755 mL | |
| 10 mM | 0.6055 mL | 3.0276 mL | 6.0551 mL | 15.1378 mL | |
| 15 mM | 0.4037 mL | 2.0184 mL | 4.0367 mL | 10.0918 mL | |
| 20 mM | 0.3028 mL | 1.5138 mL | 3.0276 mL | 7.5689 mL | |
| 25 mM | 0.2422 mL | 1.2110 mL | 2.4220 mL | 6.0551 mL | |
| 30 mM | 0.2018 mL | 1.0092 mL | 2.0184 mL | 5.0459 mL | |
| 40 mM | 0.1514 mL | 0.7569 mL | 1.5138 mL | 3.7844 mL | |
| 50 mM | 0.1211 mL | 0.6055 mL | 1.2110 mL | 3.0276 mL | |
| 60 mM | 0.1009 mL | 0.5046 mL | 1.0092 mL | 2.5230 mL | |
| 80 mM | 0.0757 mL | 0.3784 mL | 0.7569 mL | 1.8922 mL | |
| 100 mM | 0.0606 mL | 0.3028 mL | 0.6055 mL | 1.5138 mL |
Coixol Related Classifications
HY-N0936 Related Classifications
Powered by Bioz